Solid Biosciences Inc.
- SLDB
- NASDAQ
- Biotechnology
- Gene Therapy
- Duchenne Muscular Dystrophy (DMD)
- Clinical-Stage Biotech
$5.92
Today +7.05%Quote Oct 19, 2026, 08:00 PM UTC
−33.56%over the last month
Max drawdown −38.7%From 1-month high −33.6%3 months −30.0%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Solid Biosciences
Solid Biosciences Inc. is an American biotechnology firm dedicated to creating therapeutic solutions for Duchenne Muscular Dystrophy (DMD). Its most advanced experimental drug, SGT-001, is a gene transfer treatment currently in Phase I/II clinical trials, designed to encourage the production of functional dystrophin protein in patients' muscles.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
121
Founded
2013
Market value
$634.8M
Quote Oct 19
Floor
$5.75
2.8% below price
Resistance
$5.95
0.5% above price
Price vs analyst targets
23 analysts
Lowest target
$16.00Highest target
$26.00
$16.00Highest target
$26.00
- Price $5.92
- Average target $20.50
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 246% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about SLDBPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free